Low expression of miRNA-1290 associated with local invasion and recurrence in sacral chordoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chordoma is a rare, aggressive bone neoplasm with a poor prognosis and limited treatment options.
• MicroRNAs (miRNAs) are emerging as key players in chordoma pathogenesis, offering new insights into its molecular basis.
• The precise molecular mechanisms underlying chordoma remain largely unclear, necessitating the identification of novel biomarkers and therapeutic targets.

Purpose of the Study:

• To investigate the role of miRNA-1290 as a potential biomarker and therapeutic target in chordoma.
• To quantify miRNA-1290 expression in chordoma and compare it with normal tissue.
• To analyze the correlation between miRNA-1290 expression and clinical features, including tumor invasion and patient prognosis.

Main Methods:

• Quantitative real-time PCR was used to measure miRNA-1290 expression levels in chordoma tissues and fetal nucleus pulposus tissues.
• Statistical analyses were performed to assess the association between miRNA-1290 expression and clinical parameters such as tumor invasion, age, gender, tumor location, size, and recurrence-free survival (RFS).

Main Results:

• miRNA-1290 expression was significantly lower in chordoma tissues compared to fetal nucleus pulposus tissues (P=0.026).
• Low miRNA-1290 expression was associated with increased tumor invasion into surrounding muscle (P=0.013).
• A significant correlation was found between low miRNA-1290 expression and reduced recurrence-free survival (RFS) in chordoma patients (P=0.004).

Conclusions:

• miRNA-1290 may serve as a valuable prognostic biomarker for sacral chordoma.
• The downregulation of miRNA-1290 suggests its potential as an effective therapeutic target for chordoma.
• Further research into miRNA-1290's role could lead to improved treatment strategies for this challenging cancer.